Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26031830
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Curr+Gastroenterol+Rep
2015 ; 17
(6
): 21
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Next-Generation Therapeutics for IBD
#MMPMID26031830
Löwenberg M
; D'Haens G
Curr Gastroenterol Rep
2015[Jun]; 17
(6
): 21
PMID26031830
show ga
Various novel drugs have recently been evaluated in clinical trials showing
promising effects in patients with inflammatory bowel disease (IBD). Here, we
summarize the recent literature in the area of emerging therapies in the field of
IBD, with specific focus on anti-integrin antibodies, such as vedolizumab
(anti-?4?7) and etrolizumab (anti-rhuMAb ?7), and the Janus kinase (JAK)
inhibitor tofacitinib. Moreover, we will discuss efficacy and safety data of
golimumab (a new subcutaneous anti-tumor necrosis factor (TNF) antibody), Avaxia
(an orally delivered anti-TNF antibody), and Budesonide MMX; all have been
developed for the treatment of ulcerative colitis. Other therapeuticals that
might find their way to the market the coming years include the anti-mucosal
vascular addressin cell adhesion molecule (MAdCAM) PF-00547659, small molecules
(including laquinimod and the CCR9 antagonist Vercirnon), as well as an orally
active SMAD7 antisense oligonucleotide that showed clinical benefit in Crohn's
disease patients.
free
free
free
